Login to Your Account



Clinic Roundup


Friday, September 21, 2012
• Medivir AB, of Huddinge, Sweden, said HCV NS3/4A protease inhibitor simeprevir (TMC435) and non-nucleoside inhibitor TMC647055 will enter a Phase IIa interferon-free combination trial for hepatitis C virus (HCV). The open-label trial will enroll about 40 patients chronically infected with HCV genotype-1a, and the primary endpoint will be sustained virologic response 12 weeks after the end of treatment.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription